Table 3. Biochemical data at baseline, olmesartan/azelnidipine and olmesartan/trichlormethiazide treatment.
| Baseline (olmesartan alone) | Olmesartan + azelnidipine | Olmesartan + trichlormethiazide | P‐value* | |
|---|---|---|---|---|
| Bodyweight (kg) | 68.5 ± 11.6 | 68.6 ± 11.7 | 69.0 ± 11.9 | NS |
| HbA1c (%) | 7.18 ± 1.03 | 7.19 ± 0.98 | 7.40 ± 1.14 | 0.014 |
| Fasting blood glucose (mmol/L) | 6.66 (5.56–8.24) | 6.60 (5.62–8.70) | 6.71 (5.73–8.48) | NS |
| Insulin (μU/mL) | 7.80 (4.60–11.10) | 6.65 (5.00–12.40) | 8.30 (5.70–10.80) | NS |
| HOMA‐IR | 1.97 (0.99–4.07) | 1.99 (1.44–4.11) | 2.75 (1.53–3.30) | NS |
| HDL (mmol/L) | 1.31 ± 0.27 | 1.30 ± 0.25 | 1.27 ± 0.25 | NS |
| LDL (mmol/L) | 2.86 ± 0.70 | 2.99 ± 0.79 | 2.96 ± 0.78 | NS |
| Triglyceride (mmol/L) | 6.52 (4.85–10.3) | 6.63 (5.66–10.38) | 7.50 (5.45–10.15) | NS |
| Creatinine (μmol/L) | 72.5 ± 17.6 | 72.4 ± 19.3 | 75.1 ± 19.5 | 0.037 |
| eGFR (mL/min/1.73 m2) | 71.1 ± 18.4 | 72.0 ± 21.6 | 68.0 ± 17.6 | 0.011 |
| Uric acid (mmol/L) | 0.35 ± 0.09 | 0.35 ± 0.08 | 0.38 ± 0.09 | 0.005 |
| Na (mmol/L) | 61.6 ± 0.8 | 61.2 ± 0.8 | 61.2 ± 0.9 | NS |
| K (mmol/L) | 1.11 ± 0.09 | 1.08 ± 0.09 | 1.10 ± 0.11 | NS |
| Adiponectin (μg/mL) | 5.38 ± 2.53 | 5.41 ± 2.22 | 5.09 ± 2.36 | NS |
| hs‐CRP (mg/dL) | 0.055 (0.030–0.108) | 0.059 (0.031–0.109) | 0.068 (0.035–0.113) | NS |
| 8‐OHdG (ng/mg creatinine) | 4.03 ± 1.79 | 3.89 ± 2.65 | 3.99 ± 2.43 | NS |
Data are mean ± SD or median (range 25–75%). Plasma insulin level and homeostasis model assessment of insulin resistance (HOMA‐IR) were not measured in patients on insulin therapy (n = 5).
8‐OHdG, 8‐hydroxy‐2′‐deoxyguanosine; eGFR, estimated glomerular filtration rate; HDL‐C, high‐density lipoprotein cholesterol; hs‐CRP, highly‐sensitive C‐reactive protein; LDL‐C, low‐density lipoprotein cholesterol; NS, not significant.
*Comparison between olmesartan/azelnidipine and olmesartan/trichlormethiazide groups by two‐tailed Student’s t‐test or Wilcoxon signed‐rank test.